JD Health (06618.HK) Surges Nearly 4% on Strategic Alliance with Innovent Bio; Major Banks Forecast Strong H1 Earnings

Market Watcher

Jul 15

JD Health (06618.HK) jumped nearly 4% in Hong Kong trading, rising 3.31% to HK$45.2 by press time with turnover reaching HK$385 million. The rally follows Innovent Bio's announcement of a strategic cooperation agreement with JD Health. Both companies will deepen collaboration across pharmaceutical supply chains, omni-channel sales, and digital marketing, leveraging their respective strengths to deliver diverse, high-quality medicines and health services to consumers.

JD Health CEO Jin Enlin emphasized the company's commitment to improving medicine accessibility through technological innovation in healthcare, aiming to make medical resources more accessible and intelligent. He expressed optimism about exploring further partnerships in oncology and chronic disease management.

Concurrently, UBS projected JD Health's Q2 revenue growth at 17-19% year-over-year, implying first-half growth exceeding 20%—above market expectations of 18.6%. The bank cited expanding product margins and robust advertising revenue as key drivers for sustained gross margin improvement. Nomura analysts echoed the sentiment, anticipating better-than-expected H1 revenue and profits.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1143310593"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143310593\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143310593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143310593","market":"hk","top_or_hot":-1,"title":"JD Health (06618.HK) Surges Nearly 4% on Strategic Alliance with Innovent Bio; Major Banks Forecast Strong H1 Earnings","media":"Market Watcher","content":"<p>JD Health (06618.HK) jumped nearly 4% in Hong Kong trading, rising 3.31% to HK$45.2 by press time with turnover reaching HK$385 million. The rally follows Innovent Bio's announcement of a strategic cooperation agreement with JD Health. Both companies will deepen collaboration across pharmaceutical supply chains, omni-channel sales, and digital marketing, leveraging their respective strengths to deliver diverse, high-quality medicines and health services to consumers.</p>\n<p>JD Health CEO Jin Enlin emphasized the company's commitment to improving medicine accessibility through technological innovation in healthcare, aiming to make medical resources more accessible and intelligent. He expressed optimism about exploring further partnerships in oncology and chronic disease management.</p>\n<p>Concurrently, UBS projected JD Health's Q2 revenue growth at 17-19% year-over-year, implying first-half growth exceeding 20%—above market expectations of 18.6%. The bank cited expanding product margins and robust advertising revenue as key drivers for sustained gross margin improvement. Nomura analysts echoed the sentiment, anticipating better-than-expected H1 revenue and profits.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health (06618.HK) Surges Nearly 4% on Strategic Alliance with Innovent Bio; Major Banks Forecast Strong H1 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health (06618.HK) Surges Nearly 4% on Strategic Alliance with Innovent Bio; Major Banks Forecast Strong H1 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-15 21:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Market Watcher</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JD Health (06618.HK) jumped nearly 4% in Hong Kong trading, rising 3.31% to HK$45.2 by press time with turnover reaching HK$385 million. The rally follows Innovent Bio's announcement of a strategic ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0051755006.USD","symbol_name":"摩根大通中国A (dist)","start_time":0,"source_url":"","article_id":"1143310593","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143310593","pubTimestamp":1752586479,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"JD Health (06618.HK) jumped nearly 4% in Hong Kong trading, rising 3.31% to HK$45.2 by press time with turnover reaching HK$385 million. The rally follows Innovent Bio's announcement of a strategic...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","LU0051755006.USD":"摩根大通中国A (dist)","BK1583":"高瓴概念","01801":"信达生物","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1571":"互联网医疗","BK1589":"北水核心资产","06618":"京东健康","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1515":"抗疫概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","BK1247":"药品零售","BK1591":"就地过年概念","BK1142":"互联网与直销零售","BK1615":"港股-互联网"},"translate_title":"京东健康(06618.HK)与信达生物战略结盟大涨近4%；主要银行预测上半年盈利强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":1,"01801":1,"06618":1},"content_text":"JD Health (06618.HK) jumped nearly 4% in Hong Kong trading, rising 3.31% to HK$45.2 by press time with turnover reaching HK$385 million. The rally follows Innovent Bio's announcement of a strategic cooperation agreement with JD Health. Both companies will deepen collaboration across pharmaceutical supply chains, omni-channel sales, and digital marketing, leveraging their respective strengths to deliver diverse, high-quality medicines and health services to consumers.\nJD Health CEO Jin Enlin emphasized the company's commitment to improving medicine accessibility through technological innovation in healthcare, aiming to make medical resources more accessible and intelligent. He expressed optimism about exploring further partnerships in oncology and chronic disease management.\nConcurrently, UBS projected JD Health's Q2 revenue growth at 17-19% year-over-year, implying first-half growth exceeding 20%—above market expectations of 18.6%. The bank cited expanding product margins and robust advertising revenue as key drivers for sustained gross margin improvement. Nomura analysts echoed the sentiment, anticipating better-than-expected H1 revenue and profits.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}